| Q57041115 | Adaptive periodicity in the infectivity of malaria gametocytes to mosquitoes |
| Q34735569 | Chemotherapy, within-host ecology and the fitness of drug-resistant malaria parasites |
| Q36288932 | Competitive release and facilitation of drug-resistant parasites after therapeutic chemotherapy in a rodent malaria model |
| Q37282658 | Development of reverse-transcription PCR techniques to analyse the density and sex ratio of gametocytes in genetically diverse Plasmodium chabaudi infections |
| Q37085908 | Does the drug sensitivity of malaria parasites depend on their virulence? |
| Q28484134 | Enhanced transmission of drug-resistant parasites to mosquitoes following drug treatment in rodent malaria |
| Q56769896 | Fitness costs of disrupting circadian rhythms in malaria parasites |
| Q37272969 | Gametocytes: insights gained during a decade of molecular monitoring |
| Q34928604 | Malaria and trypanosome transmission: different parasites, same rules? |
| Q37287631 | Malaria diagnostics in clinical trials |
| Q39198350 | Measuring resistant-genotype transmission of malaria parasites: challenges and prospects |
| Q28550263 | Quantifying Transmission Investment in Malaria Parasites |
| Q35692528 | Relevance of undetectably rare resistant malaria parasites in treatment failure: experimental evidence from Plasmodium chabaudi |
| Q35831322 | The fitness of drug-resistant malaria parasites in a rodent model: multiplicity of infection |
| Q60629356 | Transmission stage investment of malaria parasites in response to in-host competition |
| Q55554463 | Virulence, drug sensitivity and transmission success in the rodent malaria, Plasmodium chabaudi. |